Sirnaomics Leadership

Experienced R&D team leader with a demonstrated history of working in the biotechnology industry on drug discovery and early stage development. Skilled in Cancer Research, Robotics and automation, HTS, Cell Culture and RNAi technologies. Strong operations professional with a Ph.D in Biochemistry from Imperial College, London.

George Ji has 25+ years of industrial business development and corporate management experience at multiple international firms, including GE, ASME, and Quantum Communications. Prior to joining Sirnaomics, George served as a managing director of China Biopharma, Inc., a US-listed bio-pharmaceutical company, in charge of its corporate affairs and US operations. In his current role, George manages the general operation of the company, including finance and accounting, human resources, and general administration.

20+ years leading and managing research, development and commercialization of oligonucleotide biomedical/therapeutic products in North America, Europe and Asia

Michael Molyneaux MD, MBA is a board certified physician and current Chief Medical Officer at Sirnaomics. Sirnaomics is a biopharmaceutical company discovering and developing targeted therapeutics for critical human diseases by using RNA interference (RNAi) technology. The company was founded with the mission of advancing RNAi technology using multi-targeted design of small interfering RNA (siRNA) and nanoparticle-enhanced delivery. Sirnaomics is dedicated to becoming a leader in the field of siRNA therapeutics with strong technology platforms for siRNA drug design and delivery system development. Dr. Molyneaux is currently responsible for Medical Affairs, Clinical Operations, and Regulatory Affairs activity within the Company and will lead clinical activities for IND filing in multiple therapeutic targets and pipeline development. Dr. Molyneaux excels in small company environment where tremendous drive and entrepreneurial spirit is necessary to achieve complex goals with emphasis on budget, timelines and results. He completed his MBA at the Olin Business School at Washington University in St. Louis in 2012 and obtained his MD and residency training at Dalhousie University in Nova Scotia, Canada in 1998.

Specialties: Strategic planning clinical drug development in biotech, clinical trial design and execution, pre-clinical and pipeline development, Key Opinion Leader development, CMC support, Medical safety monitoring for clinical trials, FDA experience, Key Member of IPO executive team, Fundraising, business development support, novel drug development, Executive leadership and team building,

Experienced R&D team leader with a demonstrated history of working in the biotechnology industry on drug discovery and early stage development. Skilled in Cancer Research, Robotics and automation, HTS, Cell Culture and RNAi technologies. Strong operations professional with a Ph.D in Biochemistry from Imperial College, London.

Experienced R&D team leader with a demonstrated history of working in the biotechnology industry on drug discovery and early stage development. Skilled in Cancer Research, Robotics and automation, HTS, Cell Culture and RNAi technologies. Strong operations professional with a Ph.D in Biochemistry from Imperial College, London.

Michael Molyneaux MD, MBA is a board certified physician and current Chief Medical Officer at Sirnaomics. Sirnaomics is a biopharmaceutical company discovering and developing targeted therapeutics for critical human diseases by using RNA interference (RNAi) technology. The company was founded with the mission of advancing RNAi technology using multi-targeted design of small interfering RNA (siRNA) and nanoparticle-enhanced delivery. Sirnaomics is dedicated to becoming a leader in the field of siRNA therapeutics with strong technology platforms for siRNA drug design and delivery system development. Dr. Molyneaux is currently responsible for Medical Affairs, Clinical Operations, and Regulatory Affairs activity within the Company and will lead clinical activities for IND filing in multiple therapeutic targets and pipeline development. Dr. Molyneaux excels in small company environment where tremendous drive and entrepreneurial spirit is necessary to achieve complex goals with emphasis on budget, timelines and results. He completed his MBA at the Olin Business School at Washington University in St. Louis in 2012 and obtained his MD and residency training at Dalhousie University in Nova Scotia, Canada in 1998.

Specialties: Strategic planning clinical drug development in biotech, clinical trial design and execution, pre-clinical and pipeline development, Key Opinion Leader development, CMC support, Medical safety monitoring for clinical trials, FDA experience, Key Member of IPO executive team, Fundraising, business development support, novel drug development, Executive leadership and team building,